SCHEMBL799077

SCHEMBL799077

CC(CO)NC(=O)c1ccccc1NC(=O)Nc1nc2c(s1)CN(c1ccc(F)cn1)CC2

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC27A1 Q6PCB7 1/20 0.45
LMNA P02545 4/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
NTRK1 P04629 1/20 0.41
PRKDC P78527 1/20 0.41
PIK3CG P48736 6/20 0.40
ALDH1A1 P00352 2/20 0.39
POLB P06746 1/20 0.39
GAA P10253 1/20 0.39
P2RY1 P47900 2/20 0.39
GCK P35557 2/20 0.39
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TP53 P04637 1/20 0.38
F10 P00742 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL798937 0.87 PIK3CG (0.44) LMNAMEN1KMT2APIK3CGALDH1A1
SCHEMBL799311 0.86 PIK3CG (0.44) LMNAMEN1KMT2APIK3CGALDH1A1
SCHEMBL799238 0.85 LMNA (0.44) LMNAMEN1KMT2ANTRK1PRKDC
SCHEMBL799137 0.84 PIK3CG (0.42) LMNAMEN1KMT2APIK3CGALDH1A1
SCHEMBL799317 0.84 LMNA (0.43) LMNAMEN1KMT2APIK3CGALDH1A1
SCHEMBL798946 0.83 P2RY1 (0.40) LMNAMEN1KMT2APIK3CGALDH1A1
SCHEMBL798945 0.83 P2RY1 (0.40) LMNAMEN1KMT2APIK3CGALDH1A1
SCHEMBL798962 0.83 P2RY1 (0.43) LMNAMEN1KMT2APIK3CGALDH1A1
SCHEMBL799355 0.83 P2RY1 (0.43) LMNAMEN1KMT2APIK3CGALDH1A1
SCHEMBL171964 0.82 PIK3CG (0.47) LMNAMEN1KMT2ANTRK1PRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120071475-A1 UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2012-03-22 US disclosed
US-20120071475-A1 UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071475-A1 UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY MTOR, STAT3, SLC14A1 SLC27A1 688/4885LMNA 4258/4885MEN1 2694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.